Solid Neoplasm
AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer
AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval
Takeda announces handful of pipeline cuts in effort to pivot resources
Takeda, pipeline, restructuring, Solid Neoplasm, pivot resources
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal
Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress
Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment
ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair
ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment